ResearcherOregon State UniversityActive in the last 2 years
Vidhi M. Shah
Matched on ORCID iD 0000-0001-7934-978X; OpenAlex author ID A5088136446. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 40
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 7
- The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
- Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
- The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
- A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
- Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Co-author DOI 10.3390/pharmaceutics15122651↗
- Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics14040713↗
- Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Co-author DOI 10.1016/j.canlet.2020.07.041↗
Closest collaborators
The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rosalie C. Sears · 7 shared papers, 2020–2026 · strength 1.15
- Paper The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. DOI 10.1136/jitc-2025-sitc2025.1250↗
- Paper Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. DOI 10.1016/j.canlet.2020.07.041↗
- Paper The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3437↗
- Brett C. Sheppard · 4 shared papers, 2020–2025 · strength 0.62
- Paper Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. DOI 10.1016/j.canlet.2020.07.041↗
- Paper The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3437↗
- Paper Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. DOI 10.3390/pharmaceutics14040713↗
- Motoyuki Tsuda · 4 shared papers, 2023–2025 · strength 0.62
- Paper The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3437↗
- Paper Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. DOI 10.1038/s43018-025-01003-3↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Jonathan Robert Brody · 3 shared papers, 2023–2026 · strength 0.52
- Paper The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. DOI 10.1136/jitc-2025-sitc2025.1250↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Paper Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. DOI 10.3390/pharmaceutics15122651↗
- Adam W. G. Alani · 3 shared papers, 2020–2023 · strength 0.46
- Paper Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. DOI 10.1016/j.canlet.2020.07.041↗
- Paper Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. DOI 10.3390/pharmaceutics14040713↗
- Paper Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. DOI 10.3390/pharmaceutics15122651↗
- Katherine R. Pelz · 2 shared papers, 2025–2026 · strength 0.38
- Kevin Hawthorne · 2 shared papers, 2025–2026 · strength 0.38
- Lisa M. Coussens · 2 shared papers, 2025–2026 · strength 0.37
- Paper The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. DOI 10.1136/jitc-2025-sitc2025.1250↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.37
- Paper The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. DOI 10.1136/jitc-2025-sitc2025.1250↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Isabel A. English · 2 shared papers, 2025 · strength 0.32
- Paper The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3437↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Jason M. Link · 2 shared papers, 2025 · strength 0.32
- Paper The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3437↗
- Paper A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK p… DOI 10.64898/2025.12.12.693851↗
- Brittany L. Allen-Petersen · 2 shared papers, 2022–2025 · strength 0.31
- Ellen M. Langer · 2 shared papers, 2023–2025 · strength 0.31
- Aaron J. Grossberg · 1 shared paper, 2026 · strength 0.22
- Jennifer M. Finan · 1 shared paper, 2026 · strength 0.22
- Yifei Guo · 1 shared paper, 2026 · strength 0.22
- Grace A. McCarthy · 1 shared paper, 2026 · strength 0.22
- Robert L Eil · 1 shared paper, 2026 · strength 0.22
- Zheng Xia · 1 shared paper, 2026 · strength 0.22
- Canping Chen · 1 shared paper, 2026 · strength 0.22
- Anupriya Agarwal · 1 shared paper, 2025 · strength 0.16
- Arslan Amer · 1 shared paper, 2025 · strength 0.16
- Chloe L. Bowman · 1 shared paper, 2025 · strength 0.16
- Amy S. Farrell · 1 shared paper, 2025 · strength 0.16
- Mara H. Sherman · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.